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Summary 34 
Importance  35 
Annually, over 230 million patients undergo surgery worldwide. Complications and death are 36 
frequent among high-risk patients undergoing major gastrointestinal surgery. Pooled small trials 37 
suggest outcomes may be improved by peri-operative, cardiac output-guided, hemodynamic 38 
therapy. 39 
 40 
Objective 41 
To evaluate the clinical effectiveness of a peri-operative, cardiac output-guided, hemodynamic 42 
therapy algorithm. 43 
 44 
Design 45 
Pragmatic, multi-center, randomized trial and updated systematic review.  46 
 47 
Setting 48 
17 acute hospitals in the UK.  49 
 50 
Participants 51 
734 high-risk patients; aged over 50 years undergoing major gastrointestinal surgery. 52 
 53 
Interventions 54 
Delivery of a peri-operative, cardiac output-guided, hemodynamic therapy algorithm for intra-55 
venous fluid and inotrope (dopexamine) infusion during and for six hours following surgery, 56 
compared with usual peri-operative care.  57 
 58 
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Main outcome measures 59 
The primary outcome was a composite of pre-defined moderate or major post-operative 60 
complications and mortality at 30 days following surgery. Secondary outcomes were morbidity on 61 
day 7, infectious complications, critical care free days and all cause mortality at 30 days following 62 
surgery, all cause mortality at 180 days following surgery and acute hospital length of stay.  63 
 64 
Results 65 
Baseline patient characteristics, clinical care and volumes of intra-venous fluid were similar 66 
between groups. Allocated care was non-compliant for fewer than 10% of patients in each group. 67 
The primary outcome was 36.6% for the intervention and 43.4% for usual care (RR 0.84 [0.71-68 
1.01], ARR 6.8% [−0.3% to 13.9%]; p=0.07). There was no significant difference for any of the 69 
secondary outcomes. Five intervention patients (1·4%) experienced cardiovascular serious 70 
adverse events within 24 hours compared with none in the usual care group. In pre-specified 71 
analyses,  the primary outcome treatment effect was strengthened after adjustment for protocol 72 
compliance (RR 0.80 [0.61-0.99]) and exclusion of the first ten patients recruited at each site (RR 73 
0.59 [0.41-0.84]). The findings of the updated systematic review suggest that patients receiving 74 
the intervention are less likely to develop complications (Intervention 488/1548 [31.5%] vs 75 
Controls 614/1476 [41.6%]; RR 0·77 [0·71-0·83]). 76 
 77 
Conclusions 78 
Whilst the cardiac output-guided, hemodynamic therapy algorithm was not associated with a 79 
significant reduction in post-operative complications in this trial, the findings of the updated 80 
systematic review suggest this intervention is associated with clinically important reductions in 81 
complications rates. 82 
 83 
Trial registration: http://www.controlled-trials.com/ISRCTN04386758  84 
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Short summary 85 
Findings from small trials suggest post-operative outcomes may be improved by cardiac output-86 
guided, hemodynamic therapy but this remains unconfirmed. In a multi-center randomized trial, 87 
we allocated 734 high-risk patients undergoing major gastrointestinal surgery to a hemodynamic 88 
therapy algorithm for intra-venous fluid and inotrope (dopexamine) infusion during and six hours 89 
following surgery, or usual care. The primary outcome of pre-defined moderate or major post-90 
operative complications was met by 36.6% of intervention patients and 43.4% of usual care 91 
patients (RR 0.84 [0.71-1.01]; p=0.07). Whilst not statistically significant, these findings were 92 
consistent with those of a recent Cochrane systematic review. When the systematic review was 93 
updated to include our results, significantly fewer patients developed complications having 94 
received this intervention (RR 0·70 [0·62-0·80]; p=0.01). The combined findings of the randomized 95 
trial and systematic review suggest cardiac output-guided hemodynamic therapy may be 96 
associated with a clinically important reduction in complications after surgery. 97 
 98 
  99 
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Introduction  100 
Estimates suggest that over 230 million patients undergo surgery worldwide each year with 101 
mortality reported between 1 and 4%.1,2 Complications and deaths are most frequent among 102 
high-risk patients, those who are older or have co-morbid disease and undergo major 103 
gastrointestinal or vascular surgery. Patients who develop complications, but survive to leave 104 
hospital, suffer reduced functional independence and longer-term survival.3-5 Variation in 105 
mortality indicates both the potential and the need to improve survival after major surgery.2,6 106 
Given the high volumes or surgery, even a low rate of avoidable harm will be associated with a 107 
large number of preventable deaths.  108 
 109 
It is generally accepted that intra-venous fluid and inotropic drugs have an important effect on 110 
patient outcome, in particular following major gastrointestinal surgery.  Yet, they are commonly 111 
prescribed on subjective criteria leading to wide variation in clinical practice.7 One possible 112 
solution is the use of cardiac output monitoring to guide intra-venous fluid and inotropic drug 113 
therapy as part of a hemodynamic therapy algorithm. This approach has been shown to modify 114 
inflammatory pathways, improve tissue perfusion and oxygenation,8,9 and possibly improve 115 
clinical outcomes.10-16 The current evidence base consists of a number of small trials insufficient 116 
to resolve controversies regarding potential harm associated with fluid excess, myocardial injury 117 
and invasive forms of monitoring. As a result, this approach has not been widely adopted into 118 
clinical practice. More recently, hemodynamic therapy algorithms have been adapted to utilize 119 
less invasive forms of cardiac output monitoring and lower doses of inotropic therapy for shorter 120 
periods.12 These refinements have improved the feasibility, safety and costs but clinical 121 
effectiveness remains unconfirmed. Despite this, use of hemodynamic therapy algorithms has 122 
been recommended in a report commissioned by the Centers for Medicare and Medicaid Services 123 
in the USA,17 and by the National Institute for Health and Care Excellence (NICE) in the UK,18 124 
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based on the findings of a number of small trials which suggest improved clinical outcomes. A 125 
recent Cochrane review, however, has suggested that the treatment benefit may be more 126 
marginal than previously believed.15 The mortality benefit has become less apparent in more 127 
recent trials with lower control group mortality.14  128 
 129 
In this context, we developed a peri-operative, cardiac output-guided, hemodynamic therapy 130 
algorithm for the administration of intra-venous fluid and inotropic therapy, supported by solid 131 
clinical and mechanistic evidence. Our objective was to evaluate the clinical effectiveness of this 132 
algorithm in a large, pragmatic, multi-center randomized controlled trial in high-risk patients 133 
undergoing major gastrointestinal surgery. We then conducted an updated systematic review 134 
incorporating the findings of this trial.  135 
136 
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Methods 137 
Trial design 138 
OPTIMISE was a multi-center, randomized controlled trial conducted in seventeen acute hospitals 139 
in the National Health Service in the United Kingdom. Adult patients, aged 50 years or over 140 
undergoing major abdominal surgery involving the gastrointestinal tract of expected duration 141 
greater than 90 minutes, were eligible for recruitment provided they satisfied one of the following 142 
high-risk criteria: aged 65 years or over; presence of a defined risk factor for cardiac or respiratory 143 
disease; renal impairment (serum creatinine ≥1.5 mg dl-1); diabetes mellitus; or emergency surgery. 144 
Exclusion criteria included refusal of consent, pregnancy, acute pulmonary edema (within prior 145 
seven days), acute myocardial ischemia (within prior 30 days) and patients undergoing surgery for 146 
palliative treatment only. Investigators were asked not to randomize patients where the clinician 147 
intended to use cardiac output monitoring for clinical reasons. OPTIMISE was approved by the East 148 
London & City Research Ethics Committee (09/H0703/23) and the Medical and Healthcare products 149 
Regulatory Agency and registered with Controlled Trials (ISRCTN04386758). Written informed 150 
consent was obtained from all patients prior to surgery. Site visits were performed by RP and AA 151 
for training and for source data verification. The trial protocol was lodged and is available online at 152 
www.perioperativemedicine.net/OPTIMISE. 153 
 154 
Randomization and procedures to minimize bias 155 
Randomization was performed through a dedicated, secure, web-based system. Participants were 156 
allocated to treatment groups using a computer-generated, dynamic procedure (minimization) with 157 
a random component. Participants were allocated, with an 80% probability, to the group that 158 
minimized between group differences in trial site, urgency of surgery and surgical procedure 159 
category among all participants recruited to date. This was a pragmatic effectiveness trial and it 160 
was not possible to blind all investigators to study group allocation. To minimize bias, investigators 161 
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were instructed not to reveal study group allocation unnecessarily. Patients were followed up by 162 
another investigator who, wherever possible, was unaware of allocation. Investigators performing 163 
follow-up self-assessed the extent to which they remained blinded. Outcomes were verified 164 
according to pre-defined criteria by the principal investigator or designee at each site, who was 165 
always blinded to allocation. The decision to admit a trial patient to critical care was made by 166 
clinical staff and recorded prior to randomization and surgery, allowing comparison with actual 167 
location of post-operative care. 168 
 169 
Clinical management 170 
The intervention period commenced with induction of anesthesia and continued until six hours 171 
following completion of surgery. 172 
 173 
All patients 174 
Peri-operative care for all patients was loosely defined to avoid extremes of clinical practice and 175 
practice misalignment.19 All patients received standard measures to maintain oxygenation (SpO2 176 
≥94%), hemoglobin (>80 gl-1), core temperature (37 °C) and heart rate (<100 beats min-1). 5% 177 
dextrose was administered at 1 ml kg-1 hr-1 to satisfy maintenance fluid requirements. Additional 178 
fluid was administered at the discretion of the treating clinician guided by pulse rate, arterial 179 
pressure, urine output, core-peripheral temperature gradient, serum lactate and base excess. 180 
Mean arterial pressure was maintained between 60 and 100 mmHg using an alpha adrenoceptor 181 
agonist or vasodilator, as required. Post-operative analgesia was provided by epidural infusion 182 
(bupivacaine and fentanyl) or intra-venous infusion (morphine or fentanyl). With the exception of 183 
the interventions below, all other treatment decisions were at the discretion of, and taken by, 184 
senior clinicians. 185 
 186 
 187 
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Hemodynamic therapy algorithm group patients 188 
Intervention group patients received intra-venous fluid and inotropes according to a cardiac 189 
output-guided, hemodynamic therapy algorithm (supplementary file). The algorithm was 190 
developed for OPTIMISE by an expert group. It was designed to be delivered in the operating 191 
room/post-anesthetic care unit by both medical and nursing staff, ensuring that admission for 192 
critical care was not necessary for compliance. A cardiac output monitor was chosen which could 193 
be used in conscious (extubated) patients (LiDCOrapid, LiDCO Ltd, UK). This technology has been 194 
extensively evaluated and in clinical use for more than ten years.20 The hemodynamic therapy 195 
algorithm was supported by solid clinical and mechanistic evidence and had a good cardiovascular 196 
safety profile.8-16,21-23 Intra-venous colloid solution was administered in 250ml boluses in order to 197 
achieve and maintain a maximal value of stroke volume; no attempt was made to standardize 198 
choice of colloid. Dopexamine was administered at a fixed, low dose of 0.5 μg kg-1 min-1 either 199 
through a peripheral or a central venous catheter (Cephalon Ltd, Welwyn Garden City, UK). The 200 
choice and dose of inotrope was based on the findings of a previous meta-regression analysis.13 The 201 
dose of dopexamine was reduced if the heart rate increased to 120% of baseline or 100 beats min-1 202 
(whichever was greater) for more than 30 minutes despite adequate anesthesia and analgesia. If 203 
the heart rate did not decrease despite dose reduction, then the infusion was discontinued.  204 
 205 
Usual care group patients 206 
These patients received usual peri-operative care although the use of a dynamic central venous 207 
pressure target was recommended. Cardiac output monitoring was not used in the usual care 208 
group unless specifically requested by clinical staff because of patient deterioration.  209 
 210 
Trial endpoints 211 
The primary effect estimate was the relative risk of a composite of pre-defined moderate or major 212 
post-operative complications and mortality at 30 days following surgery (supplementary file). 213 
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Secondary outcomes were: Post-Operative Morbidity Survey (POMS) defined morbidity on day 7;24 214 
infectious complications, critical care free days (number of days alive and not in critical care) and all 215 
cause mortality at 30 days following surgery; all cause mortality at 180 days following surgery; and 216 
acute hospital length of stay. Level of post-operative critical care was categorized according to 217 
standard criteria.25 Patients were followed for 30 days by visit and through local computerized 218 
records while in hospital. All patients were contacted at 30 days either by telephone for those who 219 
had left hospital or by visit for those who had not. Where necessary, investigators contacted 220 
community physicians or other hospitals, by telephone and in writing, for outstanding information 221 
describing the primary outcome. All cause mortality at 180 days was assessed through the Office 222 
for National Statistics. Data entry was performed through a dedicated, secure, web-based system. 223 
Automated validation checks included plausibility ranges and cross checks between data fields. 224 
Further data checks were performed centrally and through source data verification. 225 
 226 
Statistical analysis 227 
Assuming a type I error rate of 5%, 345 patients per group (690 total) were required to detect, with 228 
90% power, a reduction in the composite of pre-defined moderate or major post-operative 229 
complications and mortality at 30 days following surgery from 50% in the usual care group to 37.5% 230 
in the hemodynamic therapy algorithm group (absolute risk reduction 12.5%; relative risk reduction 231 
25%).12 Allowing for a 3% one-way, cross-over rate due to use of cardiac output monitoring in the 232 
usual care group, this was increased to 367 per group (734 total). A planned interim analysis was 233 
performed at halfway. Pre-defined stopping guidelines permitted early termination of the trial for 234 
harm but not effectiveness. 235 
 236 
Analyses were performed according to an a priori statistical analysis plan including all patients on 237 
an intention to treat basis (supplementary file). Categorical data were compared using Fisher’s 238 
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exact test. Differences in critical care free days and acute hospital length of stay were tested using 239 
the Wilcoxon rank-sum test. Kaplan-Meier curves were plotted for all cause mortality up to 180 240 
days following surgery. Adjustment for baseline data was made using a logistic regression model 241 
including age, gender, urgency of surgery, surgical procedure category, ASA grade, planned location 242 
following surgery, renal impairment, diabetes mellitus, risk factors for cardiac or respiratory 243 
disease and random effect of site. Baseline variables were selected for inclusion in the adjusted 244 
analysis according to anticipated relationship with outcome, including all variables used in the 245 
minimization algorithm. Results for primary and secondary outcomes are reported as relative risks 246 
(RR) with 95% confidence intervals (CI). Results for the primary outcome are additionally reported 247 
as absolute risk reduction (ARR) with 95% CI. Results of the logistic regression model are reported 248 
as adjusted odds ratios (OR) with 95% CI, with unadjusted OR for comparison. 249 
 250 
Pre-specified secondary analyses were: a modified intention to treat analysis excluding patients 251 
who did not undergo surgery; a compliance-adjusted analysis in which patients whose treatment 252 
did not comply with allocation were assumed to have the same outcome as if they had been 253 
assigned to the alternative treatment group;26 and scenario-based sensitivity analyses for missing 254 
primary outcomes (a best cases analysis assuming all missing outcomes in the intervention group 255 
were favorable and all missing outcomes in the usual care group were unfavorable and a worst 256 
case analysis assuming the reverse). Pre-specified sub-group analyses were performed: by urgency 257 
of surgery; by surgical procedure category; and by timing of recruitment (comparing the first ten 258 
patients recruited at each site with those recruited subsequently (sites recruiting fewer than ten 259 
patients were excluded). Continuous variables are presented as mean (SD) where normally 260 
distributed or median (quartiles) where not. Categorical variables are presented as n (%). Analyses 261 
were performed using Stata SE version 10.1. Significance was set at p<0.05 (two-tailed). 262 
 263 
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Systematic review 264 
Using identical methods, we updated the previous Cochrane systematic review (SR) of published 265 
randomized trials of ‘Peri-operative increase in global blood flow to explicit defined goals and 266 
outcomes following surgery’ with the findings of the OPTIMISE Trial and other published trials 267 
identified by an updated search.15 CENTRAL (Cochrane Library 2014), MEDLINE (1966 to February 268 
2014) and EMBASE (1982 to February 2014) were searched for randomized trials involving adult 269 
patients (≥ 16 years) undergoing surgery in an operating room where the intervention met the 270 
following criteria: Peri-operative administration of fluids, with or without inotropes/vasoactive 271 
drugs, targeted to increase blood flow (relative to control) against explicit measured goals. ‘Peri-272 
operative’ was defined as: initiated within 24 hours before surgery and lasting up to 6 after surgery. 273 
‘Explicit measured goals’ were defined as: cardiac index, oxygen delivery, oxygen consumption, 274 
stroke volume, mixed venous oxygen saturation, oxygen extraction ratio or lactate. We selected the 275 
following key outcomes: number of patients with complications (primary outcome variable for the 276 
OPTIMISE trial), number of infections, length of postoperative hospital stay, mortality at longest 277 
follow-up (primary outcome variable of Cochrane SR) and 28 day/30 day/hospital mortality. 278 
Treatment effects were reported as relative risks (RR) with 95% CI for clinical variables or weighted 279 
mean differences (SD) for length of hospital stay. Analyses were performed using Review Manager 280 
(RevMan 5.2.8) using fixed effects models. 281 
282 
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Results 283 
A total of 734 patients were enrolled between June 2010 and November 2012; 368 patients were 284 
allocated to the cardiac output-guided, hemodynamic therapy algorithm, and 366 to usual care. In 285 
the usual care group, one patient was randomized in error and excluded from the study (eFigure 1). 286 
Baseline patient characteristics were similar between the groups (Table 1). Most patient types 287 
were well represented with the exception of those having emergency surgery (25 patients) and 288 
those having urological or gynecological surgery involving the gut (nine patients). Clinical care 289 
outside the trial intervention was also similar (Table 2), including admission for critical care. Overall 290 
volumes of intra-venous fluid (colloid and crystalloid combined) administered during the 291 
intervention period were similar (intervention 4190 ml versus usual care 4024 ml). For usual care 292 
group patients, more intra-venous fluid was administered during than after surgery, while for 293 
intervention group patients similar volumes were administered during surgery and during the six 294 
hours following surgery. Intervention group patients received more colloid and less crystalloid than 295 
usual care group patients. With the exception of dopexamine, use of vasopressor and inotropic 296 
agents was similar between the groups. Fewer than 10% of patients in each group were non-297 
compliant with their allocated treatment (eTable 1). This was achieved through the presence of 298 
trained investigators, where necessary, to observe, advise or deliver the intervention (eTable 2). 299 
Investigator self-assessment of blinding for determination of outcomes also indicated a high rate of 300 
compliance with trial procedures (Table 3). 301 
 302 
The primary outcome, a composite of pre-defined moderate or major post-operative complications 303 
and mortality at 30 days following surgery, was met by 36.6% (134 of 366) of patients in the 304 
intervention group and by 43.4% (158 of 364) of patients in the usual care group (RR 0.84 [0.71-305 
1.01], ARR 6.8% [−0.3% to 13.9%]; p=0.07) (Table 3). Following adjustment for baseline risk factors, 306 
the observed treatment effect remained non-significant with an adjusted OR of 0.73 [0.53-1.00]; 307 
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p=0.05 (unadjusted OR 0.75 [0.56-1.01]; p=0.07). The pre-specified, modified, intention to treat 308 
analysis, in which three patients (all in the usual care group) who did not undergo surgery were 309 
excluded, had little effect on the primary outcome (RR 0.84 [0.70-1.00]; p=0.06). In the pre-310 
specified, compliance-adjusted analysis conducted using established methodology,26 the observed 311 
treatment effect was strengthened when the 65 patients whose care was non-compliant (eTable 1) 312 
were assumed to experience the same outcome as if they had been allocated to the alternative 313 
group (RR 0.80 [0.61-0.99]; p=0.037). Scenario-based sensitivity analyses demonstrated that the 314 
very small number of patients with missing primary outcome data had minimal influence on 315 
treatment effect (RR 0.84 [0.70-1.00] to 0.85 [0.71-1.02]). 316 
 317 
Five patients in the intervention group experienced serious adverse cardiac events within 24 hours 318 
of the end of the intervention period (two tachycardia, two myocardial infarction and one 319 
arrhythmia) compared with none in the usual care group (p=0.062). At 30 days following surgery, 320 
however, the incidence of cardiovascular events was similar between the groups (Table 3). There 321 
were no significant differences for any of the secondary outcomes: POMS defined morbidity on day 322 
7; infectious complications, critical care free days and all cause mortality at 30 days following 323 
surgery; all cause mortality at 180 days following surgery; and duration of acute hospital length of 324 
stay (Table 4, Figure 1). No interaction was found for urgency of surgery, the intervention was 325 
associated with a slight reduction in the primary outcome for the elective surgery sub-group.  No 326 
interaction was found for surgical procedure category, the intervention was associated with a slight 327 
reduction in the primary outcome for patients undergoing small bowel +/- pancreas surgery. A 328 
significant interaction (p=0.019) was found for timing of recruitment, the intervention was 329 
associated with a reduction in the primary outcome for patients recruited later (RR 0.59 [0.41-0.84] 330 
compared with earlier at each site (RR 1.51 [0.75-3.01] (Table 5). 331 
 332 
  333 
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Systematic review  334 
The updated literature search identified seven additional trials including OPTIMISE, to provide a 335 
total of 38 trials that included 6595 participants with 23 trials including 3024 participants providing 336 
data describing our primary outcome. Fewer patients receiving the intervention developed 337 
complications (Intervention 488/1548 [31.5%] vs Controls 614/1476 [41.6%]; RR 0·77 [0·71-0·83]) 338 
(Figure 2). The intervention was associated with a reduced incidence of post-operative infection 339 
(Intervention 182/836 patients [21·8%] vs Controls 201/790 patients [25.4%]; RR 0·81 [0·69-0.95]) 340 
and a reduced duration of hospital stay (mean reduction 0.80 days (0·97-0.62) (eFigures 2 and 3). 341 
There was no significant reduction in hospital / 28 day / 30 day mortality (Intervention 159/3215 342 
deaths [4.9%] vs Controls 206/3160 deaths [6·5%]; RR 0·82 [0·67-1·01]) and borderline evidence of 343 
a reduction in mortality at longest follow-up (Intervention 267/3215 deaths [8.3%] vs Controls 344 
327/3160 deaths [10.3%]; RR 0·86 [0·74-1·00]) (eFigures 4 and 5). 345 
 346 
347 
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Discussion 348 
The findings of the OPTIMISE trial were that in high-risk patients undergoing major abdominal 349 
surgery involving the gastrointestinal tract, when compared with usual care, use of this peri-350 
operative, cardiac output-guided, hemodynamic therapy algorithm was not associated with a 351 
significant reduction in the composite primary outcome of pre-defined moderate or major post-352 
operative complications and mortality at 30 days following surgery. However, after incorporating 353 
the results of this large clinical trial into an updated systematic review of published trials, there was 354 
evidence that cardiac output-guided, hemodynamic therapy is associated with a clinically 355 
important reduction in the number of patients who develop complications after surgery.15 In the 356 
OPTIMISE trial, there  was no difference in the secondary outcomes of POMS defined morbidity at 357 
day 7; infectious complications, critical care-free days or all cause mortality at 30 days; all cause 358 
mortality at 180 days; or acute hospital length of stay. However, the findings of the updated 359 
systematic review suggest this treatment approach is associated with a significant reduction in the 360 
number of patients who develop post-operative infection as well as in duration of hospital stay. 361 
The findings of the mortality analyses provide borderline evidence but remain consistent with 362 
benefit.   363 
 364 
This is the largest trial of a peri-operative, cardiac output-guided, hemodynamic therapy algorithm, 365 
to date. OPTIMISE was designed to address several limitations in the previous evidence base.27 The 366 
large sample size allowed for comparison of the cardiac output-guided hemodynamic therapy 367 
algorithm with usual peri-operative care, avoiding problems associated with alternative ‘control’ 368 
treatment algorithms which do not reflect typical practice.19 A large number of algorithms for 369 
cardiac output guided hemodynamic therapy have been published describing a variety of options in 370 
terms of hemodynamic end-points, use of inotropic agents and cardiac output monitoring. We used 371 
an algorithm suited to the care of patients during and after major gastrointestinal surgery, that was 372 
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supported by solid clinical and mechanistic evidence and a good cardiovascular safety profile.8,910-15, 373 
24-26 The β2-agonist dopexamine has mild inotropic and vasodilator effects and is the most widely 374 
studied agent in this context. The findings of a meta-regression analysis suggested that 375 
dopexamine infusion at low dose is associated with improved outcomes following major surgery.15 376 
Further modifications were made by an expert group to allow delivery in the operating room and 377 
post-anesthetic care unit by both medical and nursing staff and in particular to ensure admission to 378 
critical care was not necessary for compliance with the intervention. Importantly, the high rate of 379 
compliance with the hemodynamic therapy algorithm used in this trial suggests this treatment 380 
approach is feasible for use in routine clinical practice. A widely used cardiac output monitoring 381 
technology was employed (although our findings are not specific to this device). In keeping with the 382 
pragmatic nature of the trial, no attempt was made to standardize the choice of colloid in either 383 
group. Recent evidence has suggested an increased incidence of acute kidney injury in critically ill 384 
patients receiving starch-based, colloid solutions.28,29 While we do not have individual patient data 385 
describing the use of starch, a post-hoc survey of investigators suggested few patients received 386 
this. A recent systematic review identified no evidence of acute kidney injury associated with the 387 
use of starch solutions in surgical patients.30  388 
 389 
A potential weakness of OPTIMISE may be the use of a primary outcome that was a composite of 390 
moderate or major post-operative complications and mortality. The components of this outcome 391 
measure may reflect benefit, no effect or harm associated with the intervention.  We controlled for 392 
bias by assessing and grading this outcome according to pre-defined criteria and, although it is not 393 
possible to blind all clinical staff administering complex interventions, our data suggest excellent 394 
compliance with blinding for patient outcome assessment. Finally, the event rate in the usual care 395 
arm was slightly lower than expected and cross-over in terms of cardiac output monitoring in the 396 
usual care group was more frequent than predicted. These factors reduced the power of the trial, 397 
perhaps resulting in failure to achieve statistical significance for the primary outcome. Although 398 
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emergency surgery was one of our inclusion criteria, we were only able to recruit a small number of 399 
these patients. The approach to recruiting elective and emergency patients is quite different and 400 
the design of future trials should take this into account. Whilst additional research staff were often 401 
present during the trial, anesthesia and critical care staff would be able to deliver such algorithms 402 
of care with minimal training. Myocardial injury is the most important adverse effect of 403 
hemodynamic therapy algorithms; there was a low rate of cardiovascular serious adverse events 404 
within 24 hours of the intervention and the incidence of cardiovascular events was similar between 405 
the groups at 30 days following surgery. The trial findings also suggests that cardiac output-guided 406 
fluid therapy need not result in excessive fluid administration but may lead to a more individualized 407 
approach to achieving the correct dose of fluid, as and when required. Finally, a pre-specified 408 
analysis of timing of recruitment suggested that a learning curve may have existed, consistent both 409 
with an expectation for trials of complex interventions and from previous experience from 410 
implementation in this field, and this warrants consideration in future research in this area.31  411 
Conclusion 412 
In this large multi-center trial, the use of a peri-operative, cardiac output-guided, hemodynamic 413 
therapy algorithm for the administration of intra-venous fluid and a low-dose inotrope 414 
(dopexamine) was not associated with a significant reduction in a composite primary outcome of 415 
pre-defined moderate or major post-operative complications and mortality at 30 days following 416 
surgery. However, when incorporated into an updated systematic review, these findings 417 
contributed to a clinically important reduction in the number of patients who developed 418 
complications.  419 
 420 
  421 
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Figure legends 626 
 627 
Figure 1. Kaplan-Meier cumulative incidence plots for mortality by treatment allocation 628 
to 180 days from start of surgery 629 
Log rank test p-value: 0.093. 630 
 631 
 632 
Figure 2. Forest plot of meta-analysis for number of patients developing complications 633 
after surgery. 634 
 635 
636 
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Table 1: Baseline patient characteristics 637 
All data presented as n (%) 638 
* Eligibility criterion 639 
† Minimization criterion 640 
‡ Patients may have more than one risk factor 641 
 642 
 Cardiac output-guided 
hemodynamic therapy 
algorithm 
(n=368) 
Usual care 
(n=365) 
Age (years) 71.3 (8.4) 72.2 (8.6) 
Age* 
50-64 years 68 (18.5) 57 (15.6) 
≥ 65 years 300 (81.5) 308 (84.4)
Sex 
Male 237 (64.4) 229 (62.7)
Female 131 (35.6) 136 (37.3)
Urgency of surgery*† 
Elective 356 (96.7) 352 (96.4)
Emergency 12 (3.3) 13 (3.6) 
Baseline risk factors*‡ 
Renal impairment 26 (7.1) 12 (3.3) 
Diabetes mellitus 57 (15.5) 65 (17.8) 
Pre-defined risk factor for cardiac or respiratory 
disease 
117 (31.8) 118 (32.3) 
Planned surgical procedure category† 
Upper gastrointestinal 110 (29·9) 114 (31·2)
Lower gastrointestinal 167 (45·4) 163 (44·7)
Small bowel +/- pancreas 86 (23·4) 84 (23·0) 
Urological or gynecological surgery involving gut 5 (1·4) 4 (1·1) 
ASA grade 
1 21 (5.7) 24 (6.6) 
2 200 (54.5) 174 (48.1) 
3 143 (39.0) 155 (42.8)
4 3 (0.8) 9 (2.5) 
Planned location following surgery
Critical care unit (level 3) 275 (74.7) 276 (75.6)
Critical care unit (level 2) 33 (9.0) 33 (9.0) 
Post-surgical recovery unit 4 (1.1) 7 (1.9) 
Ward 56 (15.2) 49 (13.4) 
 643 
 644 
645 
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Table 2: Clinical management of patients during intervention period (during surgery and 646 
six hours following surgery) 647 
Data presented as mean (SD) or n (%) 648 
* Two patients (one in each group) missing data on anesthetic technique 649 
† Two patients (both usual care) missing data on fluids both during surgery and during six hours following 650 
surgery; one patient (hemodynamic therapy algorithm) missing data on fluids during six hours following 651 
surgery; one patient (hemodynamic therapy algorithm) missing data on fluids during surgery; one patient 652 
(usual care) missing data on crystalloid during six hours following surgery; one patient (hemodynamic 653 
therapy algorithm) missing data on blood products during six hours following surgery 654 
§Two patients (one in each group) missing data on vasopressor or inotrope agents both bolus and 655 
infusion; one patient (usual care) missing data on vasopressor or inotrope infusion 656 
 657 
 Cardiac output-guided 
hemodynamic therapy 
 algorithm 
 (n=367) 
Usual care 
(n=362) 
Duration of surgery (minutes) 270 (200-350) 260 (195-360)
Anesthetic technique* 
General anesthetic only 107 (29.2) 105 (29.1)
General anesthetic plus epidural 259 (70.8) 256 (70.9)
Intravenous crystalloid (ml)† 
During surgery 1518 (1410) 2420 (1382)
During six hours following surgery 565 (254) 670 (367) 
Intravenous colloid (ml)† 
During surgery 1465 (913) 708 (695) 
During six hours following surgery 642 (498) 226 (361) 
Blood products (ml)† 
During surgery 141 (723) 95 (542) 
During six hours following surgery 80 (555) 10 (66) 
Bolus vasopressor or inotrope agent used during 
intervention period§ 
301 (82.2) 270 (74.8) 
Infusion of vasopressor or inotrope (other than 
dopexamine) used during intervention period§ 
103 (28.1) 108 (30.0) 
Actual location of care following surgery 
Critical care unit (level 3) 258 (70.3) 246 (68.0) 
Critical care unit (level 2) 42 (11.4) 40 (11.0) 
Post-surgical recovery unit 10 (2.7) 9 (2.5)
Ward 57 (15.5) 67 (18.5) 
 658 
 659 
660 
31 
 
 Table 3: Results for primary outcome  661 
All data presented as n (%) 662 
*Six patients (three hemodynamic therapy algorithm, three usual care) missing data on self-assessment 663 
of blinding of outcome assessment 664 
†Includes three patients (two hemodynamic therapy algorithm, one usual care) who died within 30 days 665 
 666 
 Cardiac output-guided 
hemodynamic therapy 
algorithm 
(n=366) 
Usual care 
(n=364) 
Relative risk 
(95% CI) 
p-
value 
Composite 
Pre-defined moderate or major post-operative 
complications and mortality at 30 days 
following surgery 
134 (36.6) 158 (43.4) 
0.84 
 (0.71-1.01) 
0.07 
Individual elements 
Mortality 12 (3.3) 11 (3.0)  
Pulmonary embolism 4 (1.1) 1 (0.3)  
Myocardial ischemia or infarction 10 (2.7) 8 (2.2)  
Arrhythmia 39 (10.7) 40 (11.0)  
Cardiac or respiratory arrest 16 (4.4) 14 (3.8)  
Limb or digital ischemia 2 (0.5) 1 (0.3)  
Cardiogenic pulmonary edema 1 (0.3) 2 (0.5)  
Acute respiratory distress syndrome 3 (0.8) 4 (1.1)  
Gastrointestinal bleed 13 (3.6) 8 (2.2)  
Bowel infarction 2 (0.5) 5 (1.4)  
Anastomotic breakdown 12 (3.3) 16 (4.4)  
Paralytic ileus 20 (5.5) 27 (7.4)  
Acute psychosis 3 (0.8) 8 (2.2)   
Stroke 1 (0.3) 0 (0)   
Acute kidney injury 17 (4.6) 17 (4.7)  
Infection, source uncertain 11 (3.0) 9 (2.5)  
Urinary tract infection 9 (2.5) 9 (2.5)  
Surgical site infection 22 (6.0) 39 (10.7)  
Organ/space infection 20 (5.5) 36 (9.9)  
Bloodstream infection 6 (1.6) 15 (4.1)  
Nosocomial pneumonia 36 (9.8) 39 (10.7)  
Post-operative hemorrhage 6 (1.6) 4 (1.1)  
Self-assessment of blinding for outcome assessment* 
Assessor suitably blinded 342 (94.2) 349 (96.7)  
Assessor may have known allocation 9 (2.5) 6 (1.7)  
Assessor knew allocation† 12 (3.3) 6 (1.7)  
667 
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Table 4: Results for secondary outcomes 668 
Odds ratios for all cause mortality at 30 days following surgery: unadjusted 1.09 (0.48-2.45); adjusted 669 
1.20 (0.51-2.82); p=0.68 670 
Odds ratios for all cause mortality at 180 days following surgery: unadjusted 0.63 (0.39-1.04); adjusted 671 
0.61 (0.36-1.04); p=0.071 672 
Data presented as median (quartiles) or n (%) 673 
*For patients alive and in hospital on day 7 following start of surgery 674 
 675 
 676 
 Cardiac output-guided, 
hemodynamic therapy 
algorithm 
Usual care Relative 
risk (95% 
CI) 
p- 
value 
Post-Operative Morbidity 
Survey defined morbidity at 7 
days following surgery* 
182 (66.2) 
(n=275) 
195 (67.9) 
(n=287) 
0.97 
(0.87-1.09) 
0.72 
Infectious complications at 
30 days following surgery 
87 (23.8) 
(n=366) 
108 (29.7) 
(n=364) 
0.80 
(0.63-1.02) 
0.08 
Critical care free days at 30 
days following surgery 
27 (26-29) 
(n=366) 
28 (25-29) 
(n=364) 
-- 0.98 
All cause mortality at 30 days 
following surgery 
12 (3.3) 
(n=366) 
11 (3.0) 
(n=364) 
1.08 
(0.48-2.43) 
1.00 
All cause mortality at 180 
days following surgery 
28 (7.7) 
(n=363) 
42 (11.6) 
(n=361) 
0.66 
(0.42-1.05) 
0.08 
Duration of post-operative 
hospital stay 
10 (7-14) 
(n=359) 
11 (7-17) 
(n=356) 
-- 0.05 
Survivors 
10 (7-14)
(n=343) 
11 (7-17)
(n=343) 
 
Non-survivors 
7 (3-33) 
(n=16) 
16 (9-36) 
(n=13) 
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Figure 1. CONSORT flow diagram.  
 
 
1735 patients screened 
1001 excluded 
286 patient declined 
259 no research staff available 
171 senior clinician refusal 
72 patient in another trial 
69 patient unable to consent 
63 surgery cancelled/rearranged 
34 other 
47 no reason recorded 
734 patients randomised
366 patients allocated to usual care 
3 did not undergo surgery 
368 patients allocated to intervention 
1 did not undergo surgery 
366 patients in intention-to-treat 
analysis of primary outcome 
364 patients in intention-to-treat 
analysis of primary outcome 
361 patients completed trial 
(180 days) 
363 patients completed trial 
(180 days) 
2 withdrew consent 
1 randomised in error  
1 withdrew consent 
2 withdrew consent 
1 lost to follow-up 
2 withdrew consent 
1 lost to follow-up 




